Taking stock of the drug industry, from the lab to the medicine chestMay 16, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Ric Francis/AP STAT+ | FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers Normally, a deal like Amgen and Horizon's would appear to be a "slam dunk under long-established anti-trust considerations," an analyst said. By Ed Silverman STAT+ | Biden drug czar to summon naloxone makers to White House to discuss pricing Narcan, the naloxone product that received over-the-counter approval to reverse opioid overdose, remains cost-prohibitive for many consumers. By Lev Facher Pfizer RSV vaccine seen as effective against severe disease, FDA documents say The finding, in an FDA analysis, was released in advance of a Thursday meeting of a committee of outside advisers. By Helen Branswell Raphael Lafargue/Abaca/Sipa USA via AP AstraZeneca is third member to leave PhRMA in five months AstraZeneca has decided to leave the brand drug lobbying powerhouse PhRMA halfway through the year, the organization said. By Rachel Cohrs STAT+ | FTC files lawsuit to block Amgen's purchase of Horizon Therapeutics The acquisition, announced in December, was seen as another move by a large pharma company to build out its rare disease pipeline. By Andrew Joseph More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments